Results 211 to 220 of about 260,883 (251)
Some of the next articles are maybe not open access.

Schizophrenia

New England Journal of Medicine, 2003
Robert Freedman, Freedman Robert
exaly   +3 more sources

SCHIZOPHRENIA

Medical Clinics of North America, 2001
To provide the most effective care for this difficult patient population, it is helpful to remember that patients with schizophrenia have disease-intrinsic limitations that limit their ability to participate in their care. These limitations are symptoms of a disease and not volitional.
D C, Goff, S, Heckers, O, Freudenreich
openaire   +2 more sources

Schizophrenia

Psychiatric Clinics of North America, 1992
Schizophrenia occurring in childhood and adolescence has similar diagnostic, prognostic, and treatment ramifications as those noted with adult-onset schizophrenia. In assessing a child or adolescent suspected of having schizophrenia, care must be given to document DSM-III-R diagnostic criteria within the developmental framework of the patient's ...
J M, McClellan, J S, Werry
openaire   +2 more sources

Schizophrenia

Perspectives on Psychological Science, 2008
Theoretical conceptualizations of schizophrenia have undergone significant change in the past century. Through the application of behavioral science methodology, psychologists have played a major role in the pivotal scientific advances that have led us to contemporary models.
Elaine, Walker, Kevin, Tessner
openaire   +2 more sources

Schizophrenia

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 1999
Schizophrenia is among the most severe and debilitating of psychiatric disorders. Diagnosis is currently by criterion-based systems, including positive (eg, hallucinations and delusions) and negative (eg, avolition and alogia) symptoms. The importance of negative symptoms in the course and outcome of the illness is increasingly being studied.
S K, Schultz, N C, Andreasen
openaire   +4 more sources

Schizophrenia

The Lancet, 2009
Schizophrenia is still one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure. Here, we focus on the key developments in biology, epidemiology, and pharmacology of schizophrenia and provide a syndromal framework in which these aspects can be understood together.
Jim, van Os, Shitij, Kapur
openaire   +4 more sources

Schizophrenia

Nature Reviews Disease Primers
Schizophrenia is a challenging and diverse mental health condition with a lifetime prevalence of 0.4%. Schizophrenia usually manifests in late adolescence or early adulthood and is associated with high disability and a reduced life expectancy. Risk factors include genetic predisposition, prenatal and birth complications, infections and immune ...
Stefan Leucht   +10 more
openaire   +6 more sources

Schizophrenia

Psychiatric Clinics of North America, 1993
The pharmacologic treatment of the schizophrenic patient has remained substantively unchanged during the last 35 years. It is evident that as our knowledge of neuropharmacology has grown--the notion of schizophrenia being merely caused by a hyperdopaminergic state may be too simplistic.
S R, Marder   +3 more
openaire   +2 more sources

Schizophrenia

New England Journal of Medicine, 1996
exaly   +3 more sources

Polypharmacy in schizophrenia

Current Opinion in Psychiatry, 2010
Although most guidelines recommend monotherapy in schizophrenia, the combined application of multiple psychotropic agents is very common, especially in treatment-refractory cases. We review the empirical basis supporting these attempts and their relevance for clinical practice.Polypharmacy intends to address different aspects of treatment resistance ...
M, Zink   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy